JP2014519809A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519809A5 JP2014519809A5 JP2014508143A JP2014508143A JP2014519809A5 JP 2014519809 A5 JP2014519809 A5 JP 2014519809A5 JP 2014508143 A JP2014508143 A JP 2014508143A JP 2014508143 A JP2014508143 A JP 2014508143A JP 2014519809 A5 JP2014519809 A5 JP 2014519809A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- amino acid
- acid sequence
- rnase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710163270 Nuclease Proteins 0.000 claims description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 16
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 16
- 102000006382 Ribonucleases Human genes 0.000 claims description 16
- 108010083644 Ribonucleases Proteins 0.000 claims description 16
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 2
- 206010071155 Autoimmune arthritis Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 102000000989 Complement System Proteins Human genes 0.000 claims description 2
- 108010069112 Complement System Proteins Proteins 0.000 claims description 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 101000845618 Homo sapiens Deoxyribonuclease gamma Proteins 0.000 claims description 2
- 102000009490 IgG Receptors Human genes 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 208000007466 Male Infertility Diseases 0.000 claims description 2
- 206010028665 Myxoedema Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 102000054371 human DNASE1L3 Human genes 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 230000011488 interferon-alpha production Effects 0.000 claims description 2
- 201000002364 leukopenia Diseases 0.000 claims description 2
- 231100001022 leukopenia Toxicity 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000003786 myxedema Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims description 2
- 231100000572 poisoning Toxicity 0.000 claims description 2
- 230000000607 poisoning effect Effects 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 206010036601 premature menopause Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 108010036169 three prime repair exonuclease 1 Proteins 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 230000000593 degrading effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480961P | 2011-04-29 | 2011-04-29 | |
| US61/480,961 | 2011-04-29 | ||
| US201261617241P | 2012-03-29 | 2012-03-29 | |
| US61/617,241 | 2012-03-29 | ||
| PCT/US2012/035614 WO2012149440A2 (en) | 2011-04-29 | 2012-04-27 | Therapeutic nuclease compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016243950A Division JP2017114854A (ja) | 2011-04-29 | 2016-12-16 | 治療用ヌクレアーゼ組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519809A JP2014519809A (ja) | 2014-08-21 |
| JP2014519809A5 true JP2014519809A5 (https=) | 2015-06-18 |
| JP6063450B2 JP6063450B2 (ja) | 2017-01-18 |
Family
ID=47073103
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508143A Active JP6063450B2 (ja) | 2011-04-29 | 2012-04-27 | 治療用ヌクレアーゼ組成物および方法 |
| JP2016243950A Pending JP2017114854A (ja) | 2011-04-29 | 2016-12-16 | 治療用ヌクレアーゼ組成物および方法 |
| JP2018177009A Active JP6762345B2 (ja) | 2011-04-29 | 2018-09-21 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020150220A Active JP7212016B2 (ja) | 2011-04-29 | 2020-09-08 | 治療用ヌクレアーゼ組成物および方法 |
| JP2023003096A Active JP7551794B2 (ja) | 2011-04-29 | 2023-01-12 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024077060A Pending JP2024099851A (ja) | 2011-04-29 | 2024-05-10 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024151150A Pending JP2024167368A (ja) | 2011-04-29 | 2024-09-03 | 治療用ヌクレアーゼ組成物および方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016243950A Pending JP2017114854A (ja) | 2011-04-29 | 2016-12-16 | 治療用ヌクレアーゼ組成物および方法 |
| JP2018177009A Active JP6762345B2 (ja) | 2011-04-29 | 2018-09-21 | 治療用ヌクレアーゼ組成物および方法 |
| JP2020150220A Active JP7212016B2 (ja) | 2011-04-29 | 2020-09-08 | 治療用ヌクレアーゼ組成物および方法 |
| JP2023003096A Active JP7551794B2 (ja) | 2011-04-29 | 2023-01-12 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024077060A Pending JP2024099851A (ja) | 2011-04-29 | 2024-05-10 | 治療用ヌクレアーゼ組成物および方法 |
| JP2024151150A Pending JP2024167368A (ja) | 2011-04-29 | 2024-09-03 | 治療用ヌクレアーゼ組成物および方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US10202588B2 (https=) |
| EP (2) | EP3449933A1 (https=) |
| JP (7) | JP6063450B2 (https=) |
| KR (6) | KR102161657B1 (https=) |
| CN (2) | CN103930127B (https=) |
| AU (5) | AU2012249360B2 (https=) |
| BR (1) | BR112013027547B1 (https=) |
| CA (1) | CA2834626A1 (https=) |
| CL (1) | CL2013003123A1 (https=) |
| CO (1) | CO6811815A2 (https=) |
| CR (1) | CR20130598A (https=) |
| DK (1) | DK2704737T3 (https=) |
| DO (1) | DOP2013000250A (https=) |
| EA (1) | EA201391585A1 (https=) |
| EC (1) | ECSP13013060A (https=) |
| ES (1) | ES2666303T3 (https=) |
| HR (1) | HRP20180564T1 (https=) |
| HU (1) | HUE038759T2 (https=) |
| IL (5) | IL300276B2 (https=) |
| LT (1) | LT2704737T (https=) |
| MX (3) | MX351953B (https=) |
| NZ (1) | NZ616989A (https=) |
| PE (1) | PE20141172A1 (https=) |
| PH (1) | PH12013502441B1 (https=) |
| PL (1) | PL2704737T3 (https=) |
| SG (2) | SG194680A1 (https=) |
| SI (1) | SI2704737T1 (https=) |
| WO (1) | WO2012149440A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101934923B1 (ko) | 2009-11-02 | 2019-04-10 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료학적 뉴클레아제 조성물 및 방법 |
| PH12013502441B1 (en) * | 2011-04-29 | 2019-02-08 | Univ Washington | Therapeutic nuclease compositions and methods |
| US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
| EP3919505B1 (en) | 2013-01-16 | 2023-08-30 | Emory University | Uses of cas9-nucleic acid complexes |
| PL3063275T3 (pl) | 2013-10-31 | 2020-03-31 | Resolve Therapeutics, Llc | Terapeutyczne fuzje nukleaza-albumina i sposoby |
| PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
| WO2015191546A2 (en) * | 2014-06-10 | 2015-12-17 | The Board Of Regents Of The University Of Texas System | Adp-ribose detection reagents |
| WO2016069889A1 (en) * | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
| US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
| WO2017044424A1 (en) | 2015-09-08 | 2017-03-16 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
| BR112018074453A2 (pt) | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| JP7308034B2 (ja) * | 2016-07-01 | 2023-07-13 | リゾルブ セラピューティクス， エルエルシー | 最適化二重ヌクレアーゼ融合物および方法 |
| WO2018136163A2 (en) | 2016-12-09 | 2018-07-26 | Theripion, Inc. | Tandem apoa-1 fusion polypeptides |
| BR112020003670A2 (pt) | 2017-08-22 | 2020-09-01 | Sanabio, Llc | receptores de interferon solúveis e usos dos mesmos |
| US10988746B2 (en) * | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| AU2019358915B2 (en) * | 2018-10-08 | 2025-09-18 | Neutrolis, Inc. | Engineering of DNASE enzymes for manufacturing and therapy |
| US20220089786A1 (en) * | 2019-01-04 | 2022-03-24 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
| JP2020136505A (ja) | 2019-02-20 | 2020-08-31 | 株式会社Ｊｏｌｅｄ | 半導体装置および表示装置 |
| US20230062096A1 (en) * | 2020-01-11 | 2023-03-02 | Yale University | Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency |
| CA3181572A1 (en) * | 2020-06-08 | 2021-12-16 | Paul STABACH | Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections |
| CN112088903A (zh) * | 2020-09-28 | 2020-12-18 | 武汉愔紫生物科技有限公司 | 一种大分子蛋白在抗菌抗病毒消毒剂中的应用 |
| US12180521B2 (en) | 2021-02-19 | 2024-12-31 | Theripion, Inc. | Paraoxonase fusion polypeptides and related compositions and methods |
| CN115595315B (zh) * | 2021-06-28 | 2024-08-16 | 四川大学华西医院 | 核糖核酸酶i在抑制疼痛的药物中的新用途 |
| CN121518579A (zh) * | 2024-08-12 | 2026-02-13 | 上海交通大学医学院 | 一种减少线粒体dna泄露的方法 |
Family Cites Families (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5453269A (en) | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5559212A (en) | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5840840A (en) | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
| AU653937B2 (en) | 1991-04-17 | 1994-10-20 | Medisup International N.V. | Water-soluble polypeptides having high affinity for interferons alpha and beta |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| GB9300686D0 (en) | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
| US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| ATE386809T1 (de) | 1996-08-02 | 2008-03-15 | Bristol Myers Squibb Co | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| WO1998016254A1 (en) | 1996-10-17 | 1998-04-23 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7074897B2 (en) | 1997-06-16 | 2006-07-11 | Genentech, Inc. | Pro943 polypeptides |
| US20020192659A1 (en) | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6280991B1 (en) | 1997-10-15 | 2001-08-28 | Wisconsin Alumni Research Foundation | Engineered cytotoxic ribonclease |
| US5840296A (en) | 1997-10-15 | 1998-11-24 | Raines; Ronald T. | Engineered cytotoxic ribonuclease A |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6239257B1 (en) | 1998-12-30 | 2001-05-29 | Alfacell Corporation | Family of proteins belonging to the pancreatic ribonuclease a superfamily |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IL147270A0 (en) | 1999-07-02 | 2002-08-14 | Genentech Inc | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| US6175003B1 (en) | 1999-09-10 | 2001-01-16 | Alfacell Corporation | Nucleic acids encoding ribonucleases and methods of making them |
| EP1246643A4 (en) | 1999-10-14 | 2005-05-11 | Jeffery A Ledbetter | DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| BR0206985A (pt) | 2001-01-29 | 2005-04-19 | Idec Pharma Corp | Anticorpos modificados e métodos de uso |
| AU2002248571B2 (en) | 2001-03-07 | 2007-01-18 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
| JP4586310B2 (ja) | 2001-07-04 | 2010-11-24 | 株式会社Ihi | セラミックス複合部材の製造方法 |
| US20060040262A1 (en) | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| CA2489446A1 (en) | 2002-06-14 | 2003-12-24 | Wisconsin Alumni Research Foundation | Ribonuclease zymogen design |
| EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| DE60334141D1 (de) | 2002-10-15 | 2010-10-21 | Facet Biotech Corp | VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE |
| CA2503390A1 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7067298B2 (en) | 2003-03-31 | 2006-06-27 | Ambion, Inc. | Compositions and methods of using a synthetic Dnase I |
| US7666417B2 (en) * | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| JP2008504008A (ja) | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| WO2005080586A1 (en) | 2004-02-13 | 2005-09-01 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic rnases |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005115477A2 (en) | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| BRPI0514259A (pt) | 2004-08-11 | 2008-06-03 | Trubion Pharmaceuticals Inc | proteìna de fusão de domìnio de ligação |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| DE102005000921A1 (de) | 2005-01-07 | 2006-07-27 | Siemens Ag | Verfahren und Vorrichtung zur Broadband-Datenverteilung zwischen mehreren Benutzerendgeräten |
| DE102005009219A1 (de) | 2005-02-25 | 2006-08-31 | Martin-Luther-Universität Halle-Wittenberg | Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung |
| WO2006105062A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| JP2008539753A (ja) | 2005-05-09 | 2008-11-20 | グリクアート バイオテクノロジー アクチェンゲゼルシャフト | 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子 |
| US7655757B2 (en) | 2005-06-16 | 2010-02-02 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| WO2006138458A1 (en) | 2005-06-16 | 2006-12-28 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| HRP20140338T1 (hr) | 2005-07-25 | 2014-06-20 | Emergent Product Development Seattle, Llc | Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20 |
| BRPI0617688A2 (pt) | 2005-10-21 | 2011-06-07 | Hoffmann La Roche | método para expressão recombinante de um polipeptìdeo |
| BRPI0710011A2 (pt) | 2006-04-14 | 2011-08-02 | Trubion Pharmaceuticals Inc | proteìnas de ligação compreendendo articulação de imunoglobulina e regiões fc dotadas de funções efetoras fc alteradas |
| ATE547123T1 (de) | 2006-04-21 | 2012-03-15 | Mab Factory Gmbh | Antikörper-rnase-konjugat |
| GB0611444D0 (en) | 2006-06-09 | 2006-07-19 | Medical Res Council Technology | Rnase H2 complex and genes therefor |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| EP1905841A1 (en) | 2006-09-25 | 2008-04-02 | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; | Trex1 as a marker for lupus erythematosus |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| WO2008156713A2 (en) | 2007-06-12 | 2008-12-24 | Wyeth | Anti-cd20 therapeutic compositions and methods |
| JP2010532764A (ja) * | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| WO2009012600A1 (en) | 2007-07-26 | 2009-01-29 | Novagen Holding Corporation | Fusion proteins |
| EP2220125A4 (en) | 2007-11-13 | 2010-12-29 | Sapphire Energy Inc | PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE |
| EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| BRPI0913778A2 (pt) | 2008-09-26 | 2015-10-20 | Genentech Inc | "métodos de identificação de lúpus, para prever a responsividade, de diagnóstico, para auxiliar o diagnóstico, usos de um agente terapêutico, métodos de identificação, métodos, métodos para selecionar um paciente, para avaliar se um sujeito nestá em risco de desenvolver lúpus, de diagnóstico de lúpus, para prognóstico de lúpus e para auxiliar o prognóstico" |
| US8029782B2 (en) | 2008-10-01 | 2011-10-04 | Quintessence Biosciences, Inc. | Therapeutic ribonucleases |
| KR101934923B1 (ko) | 2009-11-02 | 2019-04-10 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료학적 뉴클레아제 조성물 및 방법 |
| TWI529163B (zh) | 2011-01-25 | 2016-04-11 | 陶氏農業科學公司 | 用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法 |
| KR20130129438A (ko) | 2011-02-23 | 2013-11-28 | 암젠 인크 | Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법 |
| BR112013021785A8 (pt) | 2011-02-25 | 2018-07-03 | Recombinetics Inc | animais geneticamente modificados e métodos para fazer os mesmos |
| PH12019502377A1 (en) | 2011-04-21 | 2022-11-14 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
| PH12013502441B1 (en) | 2011-04-29 | 2019-02-08 | Univ Washington | Therapeutic nuclease compositions and methods |
| US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| PL3063275T3 (pl) | 2013-10-31 | 2020-03-31 | Resolve Therapeutics, Llc | Terapeutyczne fuzje nukleaza-albumina i sposoby |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| JP7308034B2 (ja) | 2016-07-01 | 2023-07-13 | リゾルブ セラピューティクス， エルエルシー | 最適化二重ヌクレアーゼ融合物および方法 |
| JP6866739B2 (ja) * | 2017-04-13 | 2021-04-28 | 住友ゴム工業株式会社 | ゴムクローラ |
-
2012
- 2012-04-27 PH PH1/2013/502441A patent/PH12013502441B1/en unknown
- 2012-04-27 MX MX2013012612A patent/MX351953B/es active IP Right Grant
- 2012-04-27 US US13/822,215 patent/US10202588B2/en active Active
- 2012-04-27 AU AU2012249360A patent/AU2012249360B2/en active Active
- 2012-04-27 HR HRP20180564TT patent/HRP20180564T1/hr unknown
- 2012-04-27 SG SG2013080148A patent/SG194680A1/en unknown
- 2012-04-27 CA CA2834626A patent/CA2834626A1/en active Pending
- 2012-04-27 LT LTEP12777116.0T patent/LT2704737T/lt unknown
- 2012-04-27 KR KR1020197021908A patent/KR102161657B1/ko active Active
- 2012-04-27 BR BR112013027547-2A patent/BR112013027547B1/pt active IP Right Grant
- 2012-04-27 CN CN201280032451.2A patent/CN103930127B/zh active Active
- 2012-04-27 SG SG10201913930UA patent/SG10201913930UA/en unknown
- 2012-04-27 JP JP2014508143A patent/JP6063450B2/ja active Active
- 2012-04-27 KR KR1020137031347A patent/KR102006393B1/ko active Active
- 2012-04-27 NZ NZ616989A patent/NZ616989A/en unknown
- 2012-04-27 KR KR1020257006611A patent/KR20250037576A/ko active Pending
- 2012-04-27 SI SI201231276T patent/SI2704737T1/en unknown
- 2012-04-27 EP EP18167227.0A patent/EP3449933A1/en active Pending
- 2012-04-27 KR KR1020237037142A patent/KR102776415B1/ko active Active
- 2012-04-27 ES ES12777116.0T patent/ES2666303T3/es active Active
- 2012-04-27 CN CN201711217220.XA patent/CN107964539B/zh active Active
- 2012-04-27 DK DK12777116.0T patent/DK2704737T3/en active
- 2012-04-27 KR KR1020207027463A patent/KR102428875B1/ko active Active
- 2012-04-27 EP EP12777116.0A patent/EP2704737B1/en active Active
- 2012-04-27 IL IL300276A patent/IL300276B2/en unknown
- 2012-04-27 MX MX2017014091A patent/MX389061B/es unknown
- 2012-04-27 PE PE2013002425A patent/PE20141172A1/es not_active Application Discontinuation
- 2012-04-27 EA EA201391585A patent/EA201391585A1/ru unknown
- 2012-04-27 IL IL313299A patent/IL313299A/en unknown
- 2012-04-27 PL PL12777116T patent/PL2704737T3/pl unknown
- 2012-04-27 HU HUE12777116A patent/HUE038759T2/hu unknown
- 2012-04-27 KR KR1020227026432A patent/KR102596953B1/ko active Active
- 2012-04-27 WO PCT/US2012/035614 patent/WO2012149440A2/en not_active Ceased
-
2013
- 2013-10-24 IL IL229074A patent/IL229074B/en active IP Right Grant
- 2013-10-25 DO DO2013000250A patent/DOP2013000250A/es unknown
- 2013-10-28 CL CL2013003123A patent/CL2013003123A1/es unknown
- 2013-10-29 MX MX2021015735A patent/MX2021015735A/es unknown
- 2013-11-15 CR CR20130598A patent/CR20130598A/es unknown
- 2013-11-27 CO CO13279038A patent/CO6811815A2/es unknown
- 2013-11-28 EC ECSP13013060 patent/ECSP13013060A/es unknown
-
2014
- 2014-02-06 US US14/174,167 patent/US8937157B2/en active Active
-
2015
- 2015-01-19 US US14/599,567 patent/US10000745B2/en active Active
-
2016
- 2016-03-22 AU AU2016201790A patent/AU2016201790B2/en active Active
- 2016-12-16 JP JP2016243950A patent/JP2017114854A/ja active Pending
-
2018
- 2018-02-14 AU AU2018201073A patent/AU2018201073C1/en active Active
- 2018-09-21 JP JP2018177009A patent/JP6762345B2/ja active Active
- 2018-12-21 US US16/229,431 patent/US11034944B2/en active Active
-
2019
- 2019-08-29 IL IL269020A patent/IL269020B/en unknown
-
2020
- 2020-03-04 AU AU2020201619A patent/AU2020201619C1/en active Active
- 2020-09-08 JP JP2020150220A patent/JP7212016B2/ja active Active
-
2021
- 2021-05-19 US US17/324,641 patent/US12338466B2/en active Active
- 2021-08-31 IL IL285985A patent/IL285985B2/en unknown
-
2022
- 2022-06-03 AU AU2022203877A patent/AU2022203877B2/en active Active
-
2023
- 2023-01-12 JP JP2023003096A patent/JP7551794B2/ja active Active
-
2024
- 2024-05-10 JP JP2024077060A patent/JP2024099851A/ja active Pending
- 2024-09-03 JP JP2024151150A patent/JP2024167368A/ja active Pending
-
2025
- 2025-05-23 US US19/217,745 patent/US20260043012A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519809A5 (https=) | ||
| JP2013509201A5 (https=) | ||
| JP2024167368A5 (https=) | ||
| JP2020203926A5 (https=) | ||
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| US20230355728A1 (en) | Peptidic chimeric antigen receptor t cell switches and uses thereof | |
| HRP20170757T1 (hr) | Terapeutski pripravci nukleaze i postupci | |
| JP2021007390A5 (https=) | ||
| JP6199298B2 (ja) | メグルミンによって安定化されたエタネルセプト製剤 | |
| IL300276A (en) | Therapeutic nuclease compositions and methods | |
| JP6463968B2 (ja) | アルギニンを含まない腫瘍壊死因子受容体：ｆｃ融合ポリペプチド組成物およびその使用方法 | |
| JP2019530430A5 (https=) | ||
| EP3201231B1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
| AU2016287209A1 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| JP2018516566A5 (https=) | ||
| JP2022002513A (ja) | Ｕｔｉ融合タンパク質 | |
| JP2019503706A5 (https=) | ||
| JP2020536518A (ja) | 免疫調節融合タンパク質 | |
| JP2019501925A5 (https=) | ||
| CA2610804C (en) | Process for the purification of il-18 binding protein | |
| JP2009513689A5 (https=) | ||
| JP2024515607A (ja) | 抗炎症性シグレックタンパク質ならびにその製造方法及び使用方法 | |
| JP2023538533A (ja) | 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１ | |
| JP2023526551A (ja) | グルカゴン誘導体の持続型結合体の液状製剤 | |
| HRP20201752T1 (hr) | Terapeutski pripravci nukleaze i postupci |